August 19,Leading Biopharmaceutical R&D Software Solutions ProviderGenedata AG (hereinafter referred to as "Genedata") announced that it has been acquired by Danaher (NYSE: DHR), with the specific amount not disclosed.This acquisition is expected to complement Danaher's broad workflow solutions, helping to accelerate the drug discovery, development, and manufacturing of critical new therapies. Genedata, founded in 1997 and headquartered in Basel, Switzerland, is a pioneer in transforming data into intelligence for the life sciences industry.Genedata combines computational, scientific, and technical expertise with extensive knowledge in the biopharmaceutical R&D field.Enterprise software that supports large-scale experimental processes in life science researchScalable, Open, and Industry-Process-Compliant User-Friendly Solutions，To improve R&D efficiency.GenedataServing top global biopharmaceutical companies and innovative biotechnology organizations, with clients including Pfizer, Roche, Merck, GSK, Eli Lilly, and Sanofi., Bayer, Lonza and other large pharmaceutical companies; Agenua, Ligand Pharmaceuticals, Moderna and other biotechnology companies.
In the past few years, Genedata and Danaher have conducted several successful collaborations.CurrentlyThe Genedata website has also been updated with "Becoming Part of Danaher."Othmar Pfannes, Ph.D., Founder and Chief Executive Officer of Genedata"Genedata is the global market leader in digital R&D processes, dedicated to accelerating the delivery of life-saving and personalized medicines. Our achievements are rooted in the dedication and expertise of our team, whose efforts play a crucial role in earning the trust of our clients." "As an operating company under Danaher, Genedata will continue to attract top talent and address the most challenging problems faced by customers worldwide."Greg Milosevich, Vice President and Group Executive of Danaher DH Life Sciences LLC"We have long admired Genedata’s innovative software systems, which are built on a foundation of deep scientific expertise, as we have built a trusted partnership with them. Together, we are committed to supporting biopharmaceutical companies in accelerating the development of much-needed therapies by providing innovative solutions that help researchers gain high-quality insights. We are thrilled to welcome their team to Danaher and plan to continue expanding Genedata’s capabilities to meet the new technologies and demands of this rapidly evolving field."
| 
